Stem cells are unspecialized cells that can divide into more cells of the same kind or differentiate into other specialized cell types, such as nerve cells, muscle cells, skin cells, etc., under certain physiological conditions. They act as a unique internal repair system in many tissues to repair and replace worn out or damaged tissues.

Embryonic stem cells
Embryonic stem cells are obtained from human embryos. These cells have limitless expansion and pluripotency potential. Pluripotency is the ability to differentiate into any cell type. They play a significant role in regenerative medicine as well as tissue replacement after disease or injury. However, there are major ethical issues in the usage of embryonic stem cells for therapy purposes because the cells are produced by destroying an embryo. Its usage is illegal in many countries like Germany, Austria, Ireland, Italy, Portugal and Malaysia. We do not use Embryonic stem cells.

​Adult stem cells
Adult stem cells (also known as somatic stem cells) are undifferentiated cells which can be found in many types of tissues in the body (eg., bone marrow, liver and skin). Unlike the pluripotent embryonic stem cells that can divide into any cell type, Adult stem cells are multipotent. Multipotent means they can only differentiate into several distinct cell types. Their primary roles in a living organism are to maintain and repair the specific tissue in which they are found. They do not have the same ethical issues that Embryonic stem cells have. Mesenchymal stem cells (MSCs) are a form of adult stem cells that are frequently used in therapy. We use MSCs.

​Induced pluripotent stem cells (iPSCs)
iPSCs are differentiated adult cells which have undergone genetic reprogramming to become or behave like embryonic stem cells. The cells are reprogrammed to express important genes for maintaining critical embryonic stem cell properties. iPSCs are useful in drug development as well as modelling diseases today However, additional research is needed and hence, they are only used for research and currently cannot be used for therapy.

We provide only Mesenchymal Stem Cells (MSCs) derived from the Wharton’s jelly of the human Umbilical Cord (WJSC) and stem cells derived from human exfoliated deciduous teeth i.e. milk teeth (SHED).

NOTE: We DO NOT use plant stem cells or animal derived stem cells. We also DO NOT provide Cord-blood stem cells.

MSCs possess the following properties:

• Adherence to plastic – MSC must adhere to plastic when maintained in standard culture conditions using tissue culture flasks.
• Specific surface antigen (Ag) expression – ≥95% of the MSC population must express CD105, CD73 and CD90, as measured by flow cytometry.

Additionally, these cells must lack expression (≤2% positive) of CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA class II.

• Multipotent differentiation potential – The cells must be able to differentiate to osteoblasts, adipocytes and chondroblasts under standard in-vitro differentiating conditions.
• Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, Deans, R., Keating A., Prockop, Dj., Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4), 315-317

Umbilical cord tissue is a popular source of MSCs for regenerative and anti-ageing therapy. This is because MSCs from the umbilical cord originate from extraembryonic tissue and thus, have better stem cells properties when compared to other sources of MSCs. This is because of the young age of the donors.

SHED is also another popular source of MSCs as it can be easily obtained with limited ethical concern. Studies have also shown that stem cell therapy using SHED is a promising therapeutic option for neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease due to their neural crest embryonic origin. These cells are prone to undergo neurogenic differentiation both in vitro and in vivo.

Autologous stem cells are stem cells that are derived from the patients themselves who are undergoing therapy. An example would be using the patient’s own stem cells derived from the patient’s fat.

Allogeneic Stem cells are stem cells that are derived from a donor to be used in therapy and hence, not derived from the patient undergoing therapy. Stem cells harvested and cryopreserved from these donors are revived and administered into the patient. An example would include human umbilical cord stem cells.

What we offer?

We offer Allogeneic stem cells derived from the Wharton’s Jelly of the human umbilical cord and human deciduous dental pulp

1. Age of donor
   • Stem cells are more potent and have better differentiation potential when the donors of the stem cells are very young.
   • Our clients or patients tend to be above 30 years of age (mostly in the above 40 category). This means that their cells do not have the same regenerative ability that they once did when the client/patient was young.
   • The cells in the human umbilical cord are the same age as a new-born baby. Therefore, their ability to regenerate tissue is much stronger. The client/patient would get the youngest possible.
   • Since human MSCs are immunoprivileged, they will not elicit an immune response when injected into another person and there will be no rejection
   
   
2. Standardized predictable outcome
We have established standard protocols to:
• Screen the donors to ensure they are free from infectious diseases and safe to be used
• Isolate, harvest, cryopreserve and revive the stem cells.
• Screen the cells to ensure they are safe for delivery
We have also administered our allogeneic stem cells on clients/patients with different conditions and we have seen the positive effects and recorded extensive data on their progress. Based this data we’ve collected, we’re able to predict the outcome to the point where it has become standardized.


3. Less Time consuming
Taking cells from the patient itself would require:
• An extensive screening process for the donors
• Establishing a new protocol for isolation, harvesting, cryopreserving and reviving the cells since the cells are different. This would take a lot of time devising, testing and then implementing said protocol
• Screening the cells again to ensure they are safe for delivery
Using allogeneic stem cells removes the first 2 steps, as they are already established. It also will take a longer time for the autologous stem cells to work in the patient since the cells are older and less effective.

In the case of fat stem cells from the own patient, there is the added complexity of how much body fat does the patient have. Using fat cells would require ample amounts of fat, which can only be possible in overweight patients and it would also require surgery to remove that fat. And then we will have to screen the fat cells to ensure if they can be used, and if they are not viable, then the surgery would have been a waste of time and money for the client/patient. Using our allogeneic stem cells would not require any surgery to obtain the cells and there is already an established protocol with a standardized predictable outcome.